For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.
Pivotal, Randomized, Open-Label Study Of Tumor Treating Fields (TTFields, 200khz) Concomitant With Weekly Paclitaxel For The Treatment Of Recurrent Ovarian Cancer
To compare treatment using TTFields together with standard of care chemotherapy (called Paclitaxel) to standard of care chemotherapy (Paclitaxel) without TTFields. This study will help determine if using TTFields with chemotherapy is better than the usual approach of chemotherapy alone.
DiagnosisOvarian cancer that progressed after receiving a platinum-based chemotherapy
Maximum of five prior lines of completed therapy
Must be willing to receive weekly paclitaxel and able to operate the NovoTTF-100L(O) System
Measurable or non-measurable disease in the abdominal/pelvic region
Patients must sign an approved informed consent and authorization permitting release of personal health information.
- Study Device: TTFields, a device that you would carry and wear for at least 18 hours a day that delivers continuous treatment to your disease
- Group 1: You will receive standard chemotherapy (paclitaxel) associated with TTFields
- Group 2: You will receive standard chemotherapy (paclitaxel) alone
This study is expected to last 48 months.
For more information, visit ClinicalTrials.gov